TY - JOUR
T1 - Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation
AU - Nault, Jean Charles
AU - Couchy, Gabrielle
AU - Balabaud, Charles
AU - Morcrette, Guillaume
AU - Caruso, Stefano
AU - Blanc, Jean Frederic
AU - Bacq, Yannick
AU - Calderaro, Julien
AU - Paradis, Valérie
AU - Ramos, Jeanne
AU - Scoazec, Jean Yves
AU - Gnemmi, Viviane
AU - Sturm, Nathalie
AU - Guettier, Catherine
AU - Fabre, Monique
AU - Savier, Eric
AU - Chiche, Laurence
AU - Labrune, Philippe
AU - Selves, Janick
AU - Wendum, Dominique
AU - Pilati, Camilla
AU - Laurent, Alexis
AU - De Muret, Anne
AU - Le Bail, Brigitte
AU - Rebouissou, Sandra
AU - Imbeaud, Sandrine
AU - Laurent, Christophe
AU - Saric, Jean
AU - Frulio, Nora
AU - Castain, Claire
AU - Dujardin, Fanny
AU - Benchellal, Zin
AU - Bourlier, Pascal
AU - Azoulay, Daniel
AU - Luciani, Alain
AU - Pageaux, Georges Philippe
AU - Fabre, Jean Michel
AU - Vilgrain, Valerie
AU - Belghiti, Jacques
AU - Bancel, Brigitte
AU - Boleslawski, Emmanuel
AU - Letoublon, Christophe
AU - Vaillant, Jean Christophe
AU - Prévôt, Sophie
AU - Castaing, Denis
AU - Jacquemin, Emmanuel
AU - Peron, Jean Marie
AU - Quaglia, Alberto
AU - Paye, François
AU - Terraciano, Luigi
AU - Mazzaferro, Vincenzo
AU - Saint Paul, Marie Christine
AU - Terris, Benoit
AU - Bioulac-Sage, Paulette
AU - Letouzé, Eric
AU - Zucman-Rossi, Jessica
N1 - Publisher Copyright:
© 2017 AGA Institute
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Background & Aims Hepatocellular adenomas (HCAs) are benign liver tumors that can be assigned to molecular subtypes based on inactivating mutations in hepatocyte nuclear factor 1A, activating mutations in β-catenin, or activation of inflammatory signaling pathways. We aimed to update the classification system for HCA and associate the subtypes with disease risk factors and complications. Methods We analyzed expression levels of 20 genes and sequenced exon regions of 8 genes (HNF1A, IL6ST, CTNNB1, FRK, STAT3, GNAS, JAK1, and TERT) in 607 samples of 533 HCAs from 411 patients, collected from 28 centers mainly in France from 2000 and 2014. We performed gene expression profile, RNA sequence, whole-exome and genome sequence, and immunohistochemical analyses of select samples. Molecular data were associated with risk factors, histopathology, bleeding, and malignant transformation. Results Symptomatic bleeding occurred in 14% of the patients (85% of cases were female, median age, 38 years); 7% of the nodules were borderline between HCA and hepatocellular carcinoma, and 3% of patients developed hepatocellular carcinoma from HCA. Based on molecular features, we classified HCA into 8 subgroups. One new subgroup, composed of previously unclassified HCA, represented 4% of HCAs overall and was associated with obesity and bleeding. These tumors were characterized by activation of sonic hedgehog signaling, due to focal deletions that fuse the promoter of INHBE with GLI1. Analysis of genetic heterogeneity among multiple HCAs, from different patients, revealed a molecular subtype field effect; multiple tumors had different mutations that deregulated similar pathways. Specific molecular subtypes of HCA associated with various HCA risk factors, including imbalances in estrogen or androgen hormones. Specific molecular subgroup of HCA with β-catenin and sonic hedgehog activation associated with malignant transformation and bleeding, respectively. Conclusions Using sequencing and gene expression analyses, we identified a subgroup of HCA characterized by fusion of the INHBE and GLI1 genes and activation of sonic hedgehog pathway. Molecular subtypes of HCAs associated with different patients’ risk factors for HCA, disease progression, and pathology features of tumors. This classification system might be used to select treatment strategies for patients with HCA.
AB - Background & Aims Hepatocellular adenomas (HCAs) are benign liver tumors that can be assigned to molecular subtypes based on inactivating mutations in hepatocyte nuclear factor 1A, activating mutations in β-catenin, or activation of inflammatory signaling pathways. We aimed to update the classification system for HCA and associate the subtypes with disease risk factors and complications. Methods We analyzed expression levels of 20 genes and sequenced exon regions of 8 genes (HNF1A, IL6ST, CTNNB1, FRK, STAT3, GNAS, JAK1, and TERT) in 607 samples of 533 HCAs from 411 patients, collected from 28 centers mainly in France from 2000 and 2014. We performed gene expression profile, RNA sequence, whole-exome and genome sequence, and immunohistochemical analyses of select samples. Molecular data were associated with risk factors, histopathology, bleeding, and malignant transformation. Results Symptomatic bleeding occurred in 14% of the patients (85% of cases were female, median age, 38 years); 7% of the nodules were borderline between HCA and hepatocellular carcinoma, and 3% of patients developed hepatocellular carcinoma from HCA. Based on molecular features, we classified HCA into 8 subgroups. One new subgroup, composed of previously unclassified HCA, represented 4% of HCAs overall and was associated with obesity and bleeding. These tumors were characterized by activation of sonic hedgehog signaling, due to focal deletions that fuse the promoter of INHBE with GLI1. Analysis of genetic heterogeneity among multiple HCAs, from different patients, revealed a molecular subtype field effect; multiple tumors had different mutations that deregulated similar pathways. Specific molecular subtypes of HCA associated with various HCA risk factors, including imbalances in estrogen or androgen hormones. Specific molecular subgroup of HCA with β-catenin and sonic hedgehog activation associated with malignant transformation and bleeding, respectively. Conclusions Using sequencing and gene expression analyses, we identified a subgroup of HCA characterized by fusion of the INHBE and GLI1 genes and activation of sonic hedgehog pathway. Molecular subtypes of HCAs associated with different patients’ risk factors for HCA, disease progression, and pathology features of tumors. This classification system might be used to select treatment strategies for patients with HCA.
KW - Benign
KW - HCC
KW - SHH
KW - Tumor Progression
UR - http://www.scopus.com/inward/record.url?scp=85014329748&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2016.11.042
DO - 10.1053/j.gastro.2016.11.042
M3 - Article
C2 - 27939373
AN - SCOPUS:85014329748
SN - 0016-5085
VL - 152
SP - 880-894.e6
JO - Gastroenterology
JF - Gastroenterology
IS - 4
ER -